Remegen Co. Ltd. Class ASSE: 688331

Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab the Treatment of HER2-Low Expressing Breast Cancer with Liver Metastasis

· Issued by Remegen Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab the Treatment of HER2-Low Expressing Breast Cancer with Liver Metastasis

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis